scholarly journals Impact of Barrett oesophagus diagnoses and endoscopies on oesophageal cancer survival in the UK: A cohort study

2021 ◽  
Author(s):  
Judith Offman ◽  
Francesca Pesola ◽  
Rebecca C. Fitzgerald ◽  
Willie Hamilton ◽  
Peter Sasieni
Keyword(s):  
Cohort Study ◽  
Oesophageal Cancer ◽  
Cancer Survival ◽  
The Uk ◽  
Barrett Oesophagus

scholarly journals Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study

2017 ◽  
Vol 47 (2) ◽  
pp. 279-288 ◽  
Author(s):  
J. Busby ◽  
Ú. McMenamin ◽  
A. Spence ◽  
B. T. Johnston ◽  
C. Hughes ◽  
...  
Keyword(s):  
Cohort Study ◽  
Oesophageal Cancer ◽  
Angiotensin Receptor Blocker ◽  
Cancer Survival ◽  
Population Based ◽  
Receptor Blocker ◽  
Angiotensin Receptor

scholarly journals International trends in oesophageal cancer survival by histological subtype between 1995 and 2014

Gut ◽  
2020 ◽  
pp. gutjnl-2020-321089 ◽  
Author(s):  
Eileen Morgan ◽  
Isabelle Soerjomataram ◽  
Anna T Gavin ◽  
Mark J Rutherford ◽  
Piers Gatenby ◽  
...  
Keyword(s):  
New Zealand ◽  
Oesophageal Cancer ◽  
Cancer Survival ◽  
Age Groups ◽  
International Comparisons ◽  
Cancer Registries ◽  
Incidence Rates ◽  
International Trends ◽  
Younger Age ◽  
The Uk

IntroductionSurvival from oesophageal cancer remains poor, even across high-income countries. Ongoing changes in the epidemiology of the disease highlight the need for survival assessments by its two main histological subtypes, adenocarcinoma (AC) and squamous cell carcinoma (SCC).MethodsThe ICBP SURVMARK-2 project, a platform for international comparisons of cancer survival, collected cases of oesophageal cancer diagnosed 1995 to 2014, followed until 31st December 2015, from cancer registries covering seven participating countries with similar access to healthcare (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK). 1-year and 3-year age-standardised net survival alongside incidence rates were calculated by country, subtype, sex, age group and period of diagnosis.Results111 894 cases of AC and 73 408 cases of SCC were included in the analysis. Marked improvements in survival were observed over the 20-year period in each country, particularly for AC, younger age groups and 1 year after diagnosis. Survival was consistently higher for both subtypes in Australia and Ireland followed by Norway, Denmark, New Zealand, the UK and Canada. During 2010 to 2014, survival was higher for AC compared with SCC, with 1-year survival ranging from 46.9% (Canada) to 54.4% (Ireland) for AC and 39.6% (Denmark) to 53.1% (Australia) for SCC.ConclusionMarked improvements in both oesophageal AC and SCC survival suggest advances in treatment. Less marked improvements 3 years after diagnosis, among older age groups and patients with SCC, highlight the need for further advances in early detection and treatment of oesophageal cancer alongside primary prevention to reduce the overall burden from the disease.

scholarly journals International variation in oesophageal and gastric cancer survival 2012–2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)

Gut ◽  
2021 ◽  
pp. gutjnl-2021-325266
Author(s):  
Melina Arnold ◽  
Eileen Morgan ◽  
Aude Bardot ◽  
Mark J Rutherford ◽  
Jacques Ferlay ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
New Zealand ◽  
Oesophageal Cancer ◽  
Cancer Survival ◽  
High Income ◽  
Stage At Diagnosis ◽  
Histological Subtype ◽  
Histological Subtypes ◽  
The Uk ◽  
Localised Disease

ObjectiveTo provide the first international comparison of oesophageal and gastric cancer survival by stage at diagnosis and histological subtype across high-income countries with similar access to healthcare.MethodsAs part of the ICBP SURVMARK-2 project, data from 28 923 patients with oesophageal cancer and 25 946 patients with gastric cancer diagnosed during 2012–2014 from 14 cancer registries in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK) were included. 1-year and 3-year age-standardised net survival were estimated by stage at diagnosis, histological subtype (oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma (OSCC)) and country.ResultsOesophageal cancer survival was highest in Ireland and lowest in Canada at 1 (50.3% vs 41.3%, respectively) and 3 years (27.0% vs 19.2%) postdiagnosis. Survival from gastric cancer was highest in Australia and lowest in the UK, for both 1-year (55.2% vs 44.8%, respectively) and 3-year survival (33.7% vs 22.3%). Most patients with oesophageal and gastric cancer had regional or distant disease, with proportions ranging between 56% and 90% across countries. Stage-specific analyses showed that variation between countries was greatest for localised disease, where survival ranged between 66.6% in Australia and 83.2% in the UK for oesophageal cancer and between 75.5% in Australia and 94.3% in New Zealand for gastric cancer at 1-year postdiagnosis. While survival for OAC was generally higher than that for OSCC, disparities across countries were similar for both histological subtypes.ConclusionSurvival from oesophageal and gastric cancer varies across high-income countries including within stage groups, particularly for localised disease. Disparities can partly be explained by earlier diagnosis resulting in more favourable stage distributions, and distributions of histological subtypes of oesophageal cancer across countries. Yet, differences in treatment, and also in cancer registration practice and the use of different staging methods and systems, across countries may have impacted the comparisons. While primary prevention remains key, advancements in early detection research are promising and will likely allow for additional risk stratification and survival improvements in the future.

scholarly journals Retrospective cohort study of 925 OAGB procedures. The UK MGB/OAGB collaborative group

2019 ◽  
Vol 69 ◽  
pp. 13-18 ◽  
Author(s):  
A. Hussain ◽  
M. Van den Bossche ◽  
D.D. Kerrigan ◽  
A. Alhamdani ◽  
C. Parmar ◽  
...  
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Collaborative Group ◽  
The Uk

scholarly journals Review of orthopaedic trauma surgery during the peak of COVID-19 pandemic – An observational cohort study in the UK

2021 ◽  
Author(s):  
Chiranjit De ◽  
Nimrath Kainth ◽  
Pratap Karavadra Harbham ◽  
Margaret Brooks ◽  
Sujit Agarwal
Keyword(s):  
Cohort Study ◽  
Trauma Surgery ◽  
Observational Cohort Study ◽  
Orthopaedic Trauma ◽  
Observational Cohort ◽  
The Uk

scholarly journals Clinical laboratory tests and five-year incidence of major depressive disorder: a prospective cohort study of 433,890 participants from the UK Biobank

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Michael Wainberg ◽  
Stefan Kloiber ◽  
Breno Diniz ◽  
Roger S. McIntyre ◽  
Daniel Felsky ◽  
...  
Keyword(s):  
Public Health ◽  
Major Depressive Disorder ◽  
Cohort Study ◽  
Confidence Interval ◽  
Depressive Disorder ◽  
Blood Cell ◽  
Biological Processes ◽  
Uk Biobank ◽  
Major Depressive ◽  
The Uk

AbstractPrevention of major depressive disorder (MDD) is a public health priority. Identifying biomarkers of underlying biological processes that contribute to MDD onset may help address this public health need. This prospective cohort study encompassed 383,131 white British participants from the UK Biobank with no prior history of MDD, with replication in 50,759 participants of other ancestries. Leveraging linked inpatient and primary care records, we computed adjusted odds ratios for 5-year MDD incidence among individuals with values below or above the 95% confidence interval (<2.5th or >97.5th percentile) on each of 57 laboratory measures. Sensitivity analyses were performed across multiple percentile thresholds and in comparison to established reference ranges. We found that indicators of liver dysfunction were associated with increased 5-year MDD incidence (even after correction for alcohol use and body mass index): elevated alanine aminotransferase (AOR = 1.35, 95% confidence interval [1.16, 1.58]), aspartate aminotransferase (AOR = 1.39 [1.19, 1.62]), and gamma glutamyltransferase (AOR = 1.52 [1.31, 1.76]) as well as low albumin (AOR = 1.28 [1.09, 1.50]). Similar observations were made with respect to endocrine dysregulation, specifically low insulin-like growth factor 1 (AOR = 1.34 [1.16, 1.55]), low testosterone among males (AOR = 1.60 [1.27, 2.00]), and elevated glycated hemoglobin (HbA1C; AOR = 1.23 [1.05, 1.43]). Markers of renal impairment (i.e. elevated cystatin C, phosphate, and urea) and indicators of anemia and macrocytosis (i.e. red blood cell enlargement) were also associated with MDD incidence. While some immune markers, like elevated white blood cell and neutrophil count, were associated with MDD (AOR = 1.23 [1.07, 1.42]), others, like elevated C-reactive protein, were not (AOR = 1.04 [0.89, 1.22]). The 30 significant associations validated as a group in the multi-ancestry replication cohort (Wilcoxon p = 0.0005), with a median AOR of 1.235. Importantly, all 30 significant associations with extreme laboratory test results were directionally consistent with an increased MDD risk. In sum, markers of liver and kidney dysfunction, growth hormone and testosterone deficiency, innate immunity, anemia, macrocytosis, and insulin resistance were associated with MDD incidence in a large community-based cohort. Our results support a contributory role of diverse biological processes to MDD onset.

Sign in / Sign up

Export Citation Format

Share Document